Roche’s key growth products did not perform well in the first quarter and there are now some signs of fatigue. There is still no visible impact on Ocrevus’ trajectory from last year's launch ...

you cannot produce 10,000 products in every country," said Schinecker. He said Roche was arguing it would "produce as much in volume as you use in the U.S., because some of that you may export".

Roche also announced the initiation of a Phase ... with a Phase III trontinemab programme and continue to expand our diagnostic solutions,” said Levi Garraway, M.D., Ph.D., Roche’s Chief ...

HEMLIBRA has strong market potential due to its unique, subcutaneous prophylactic treatment for Hemophilia A, including patients with and wit ...